GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (SHSE:603259) » Definitions » Forward PE Ratio

Wuxi AppTec Co (SHSE:603259) Forward PE Ratio : 12.27 (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuxi AppTec Co Forward PE Ratio?

Wuxi AppTec Co's Forward PE Ratio for today is 12.27.

Wuxi AppTec Co's PE Ratio without NRI for today is 12.80.

Wuxi AppTec Co's PE Ratio for today is 13.25.


Wuxi AppTec Co Forward PE Ratio Historical Data

The historical data trend for Wuxi AppTec Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co Forward PE Ratio Chart

Wuxi AppTec Co Annual Data
Trend 2022-12 2023-11 2024-04
Forward PE Ratio
22.88 18.83 12.27

Wuxi AppTec Co Quarterly Data
2022-06 2022-09 2022-12 2023-06 2023-09 2024-03
Forward PE Ratio 39.53 20.49 22.88 18.02 17.89 13.19

Competitive Comparison of Wuxi AppTec Co's Forward PE Ratio

For the Diagnostics & Research subindustry, Wuxi AppTec Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuxi AppTec Co's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Wuxi AppTec Co's Forward PE Ratio falls into.



Wuxi AppTec Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Wuxi AppTec Co  (SHSE:603259) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Wuxi AppTec Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co (SHSE:603259) Business Description

Traded in Other Exchanges
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.

Wuxi AppTec Co (SHSE:603259) Headlines

No Headlines